TAILIEUCHUNG - HEMATOPOIETIC GROWTH FACTORS IN ONCOLOGY BASIC SCIENCE AND CLINICAL THERAPEUTICS

Several hematopoietic growth factors (HGFs) have achieved widespread clinical application. In the United States alone, more than US $5 billion per year of the health care budget is spent on these factors. The first patients were treated with recombinant human erythropoietin (rHuEPO, epoetin alfa, Epogen®) in 1985 and the first patients received recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim, Neupogen®) or recombinant human granulocyte-macrophage colonystimulating factor (rHuGM-CSF, sargramostim, Leukine® or Prokine®) in 1986. The first agent promoting platelet recovery was formally approved in 1997 (recombinant human interleukin-11 [rHuIL-11], oprelvekin, Neumega®). In 2002, sustained-duration derivative r-metHuG-CSF (pegfilgrastim, Neulasta®) was formally approved for clinical use | CANCER DRUG DISCOVERY AND DEVELOPMENT Hematopoietic Growth Factors in Oncology Hematopoietic Growth Factors in Oncology Cancer Drug Discovery and Development Beverly A. Teicher Series Editor Proteasome Inhibitors in Cancer Therapy edited by Julian Adams 2004 Nucleic Acid Theapeutics in Cancer edited by Alan M. Gewirtz 2004 Cancer Chemoprevention Volume 1 Promising Cancer Chemopreventive Agents edited by Gary J. Kelloff Ernest T. Hawk and Caroline C. Sigman 2004 DNA Repair in Cancer Therapy edited by Lawrence C. Panasci and Moulay A. Alaoui-Jamali 2004 Hematopoietic Growth Factors in Oncology Basic Science and Clinical Therapeutics edited by George Morstyn MaryAnn Foote and Graham J. Lieschke 2004 Handbook of Anticancer Pharmacokinetics and Pharmacodynamics edited by William D. Figg and Howard L. McLeod 2004 Anticancer Drug Development Guide Preclinical Screening Clinical Trials and Approval Second Edition edited by Beverly A. Teicher and Paul A. Andrews 2004 Handbook of Cancer Vaccines edited by Michael A. Morse Timothy M. Clay and Kim H. Lyerly 2004 Drug Delivery Systems in Cancer Therapy edited by Dennis M. Brown 2003 Oncogene-Directed Therapies edited by Janusz Rak 2003 Cell Cycle Inhibitors in Cancer Therapy Current Strategies edited by Antonio Giordano and Kenneth J. Soprano 2003 Chemoradiation in Cancer Therapy edited by Hak Choy 2003 Fluoropyrimidines in Cancer Therapy edited by Youcef M. Rustum 2003 Targets for Cancer Chemotherapy Transcription Factors and Other Nuclear Proteins edited by Nicholas B. La Thangue and Lan R. Bandara 2002 Tumor Targeting in Cancer Therapy edited by Michel Pagé 2002 Hormone Therapy in Breast and Prostate Cancer edited by V. Craig Jordan and Barrington J. A. Furr 2002 Tumor Models in Cancer Research edited by Beverly A. Teicher 2002 Tumor Suppressor Genes in Human Cancer edited by David E. Fisher 2001 Matrix Metalloproteinase Inhibitors in Cancer Therapy edited by Neil J. Clendeninn and Krzysztof Appelt 2001 Farnesyltransferase .

• Y học thường thức
• Cytokine Signaling
• Peptide Agonists
• HEMATOPOIETIC GROWTH
• Erythropoietic Factors
• Thrombopoietin Factors
• Stem Cell Factor
• BMC Cancer
• Breast cancer
• Breast invasive carcinoma
• Suppressor of cytokine signaling
• The Cancer Genome Atlas
• Journal of Biology
• Pleiotropic cytokine
• TNFR1 signaling pathway
• Proline rich PPAP region
• SH3 domain containing proteins
• TNFR1 SH3 domain modifications
• Ovarian cancer
• Quantitative real time PCR
• Physiological processes
• Suppressor of cytokine signaling 3
• báo cáo khoa học
• báo cáo y học
• công trình nghiên cứu về y học
• tài liệu về y học
• cách trình bày báo cáo
• trình bày báo cáo
• tài liệu báo cáo khoa học
• kiến thức y học
• nghiên cứu y học
• Report medicine
• traditional medicine
• scientific reports
• biochemical studies
• environmental medicine
• Crystal structure
• Enhancing Signal
• Dampen Signaling
• Adaptor Proteins
• Signal Transduction
• Cytokine Regulation
• Apoptotic Mediators
• báo cáo hóa học
• công trình nghiên cứu về hóa học
• tài liệu về hóa học
• cáo cáo y học
• JAK2 gene
• Myeloid hematopoiesis during
• Zebrafish embryogenesis
• Cytokine signaling pathways
• Janus kinase
• Prostate cancer
• Tumor suppressor
• Suppressor of cytokine signaling 1
• Micro RNA mediated repression
• Renal cell carcinoma
• Chemokine receptor signaling pathways
• CXCR2 receptor
• Angiogenic chemokines
• TGF beta
• Chemotactic cytokine
• Chemo resistance
• Tumor microenvironment
• Anaplastic large cell lymphoma
• Anaplastic lymphoma kinase
• Therapeutic significance
• Cytokine independent
• Cancer aggressiveness
• Cytokine secretion profiles
• NF κB signaling pathway
• Anaplastic thyroid cancer
• MiR 155 promotes
• Directly targeting SOCS1